The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•14 May 2026•

1 min read

Invivyd Reports Q1 Earnings Miss as Clinical Development Costs Surge

Key Facts

1Invivyd reported an EPS loss of -$0.13, missing the analyst consensus estimate of -$0.08.

2The company's revenue reached $13.74 million, falling short of the estimated $18.04 million.

3Net product revenue from PEMGARDA grew 22% year-over-year to $11.30 million.

Invivyd reported Q1 2026 financial results featuring an EPS loss of -$0.13, missing the analyst consensus estimate of -$0.08. Revenue for the period reached $13.74 million, falling short of the $18.04 million anticipated by markets according to reports. Despite the overall miss, net product revenue from PEMGARDA grew 22% year-over-year to reach $11.30 million.

The earnings miss was primarily driven by higher operating expenses related to the pivotal DECLARATION study for the company's new antibody candidate, VYD2311. This increase in R&D spending reflects a broader trend among clinical-stage biotech firms prioritizing pipeline advancement over short-term profitability, per market data. Analysts from Zacks Investment Research noted that the double miss on both top and bottom lines reflects the high cost of maintaining competitive clinical momentum.

The stock IVVD remains under watch following the report at close May 14, 2026. Looking ahead, investors will focus on clinical milestone updates for VYD2311 as primary catalysts. While the economic calendar shows several upcoming Fed speeches, the immediate trajectory for Invivyd will likely depend on its ability to manage cash burn relative to the commercial growth of PEMGARDA.